Prevention: Vaccine Trial

The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.

September 30, 2019 By Benjamin Ryan

The third current major trial to examine a promising HIV vaccine candidate is launching in late 2019, enrolling cisgender men and transgender individuals who have sex with men or trans people. The Phase III, placebo-controlled efficacy study, called Mosaico, will run out of approximately 55 clinical research sites in the United States, Mexico, South America and Europe.

Mosaico will enroll 3,800 HIV-negative 18- to 60-year-old people who are in good health and at risk of acquiring the virus. They can't be taking pre-exposure prophylaxis (PrEP) upon enrolling but may start PrEP during the trial. Over the course of a year, those randomized to the active vaccine group will receive four doses of a vaccine candidate, known as Ad26.Mos4.HIV, that recently drove a strong immune response in earlier trials. The participants will be followed for 18 months. The study should wrap up during the first half of 2023.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.poz.com/article/prevention-vaccine-trial